Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

被引:120
作者
Mitra, A. [1 ,2 ]
Fisher, C. [1 ,2 ]
Foster, C. S. [3 ]
Jameson, C. [2 ]
Barbachanno, Y. [2 ]
Bartlett, J. [1 ]
Bancroft, E. [2 ]
Doherty, R. [1 ]
Kote-Jarai, Z. [1 ]
Peock, S. [4 ]
Easton, D.
Eeles, R. [1 ,2 ]
机构
[1] Inst Canc Res, Translat Canc Genet Team, Sutton SM2 5NG, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Canc Genet Unit, London, England
[3] Royal Liverpool Univ Hosp, Dept Histopathol, Liverpool, Merseyside, England
[4] Strangeways Res Lab, CR UK Genet Epidemiol Unit, Cambridge CB1 4RN, England
基金
英国医学研究理事会;
关键词
prostate cancer; BRCA1 and BRCA2; prostate pathology;
D O I
10.1038/sj.bjc.6604132
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly higher ( Gleason scores 8, 9 or 10, P = 0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial.
引用
收藏
页码:502 / 507
页数:6
相关论文
共 31 条
[1]   Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists [J].
Allsbrook, WC ;
Mangold, KA ;
Johnson, MH ;
Lane, RB ;
Lane, CG ;
Amin, MB ;
Bostwick, DG ;
Humphrey, PA ;
Jones, EC ;
Reuter, VE ;
Sakr, W ;
Sesterhenn, IA ;
Troncoso, P ;
Wheeler, TM ;
Epstein, JI .
HUMAN PATHOLOGY, 2001, 32 (01) :74-80
[2]   Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologists [J].
Allsbrook, WC ;
Mangold, KA ;
Johnson, MH ;
Lane, RB ;
Lane, CG ;
Epstein, JI .
HUMAN PATHOLOGY, 2001, 32 (01) :81-88
[3]   Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome [J].
Berney, D. M. ;
Fisher, G. ;
Kattan, M. W. ;
Oliver, R. T. D. ;
Moller, H. ;
Fearn, P. ;
Eastham, J. ;
Scardino, P. ;
Cuzick, J. ;
Reuter, V. E. ;
Foster, C. S. .
HISTOPATHOLOGY, 2007, 51 (04) :452-457
[4]   Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading [J].
Berney, Daniel M. ;
Fisher, Gabrielle ;
Kattan, Michael W. ;
Oliver, R. Timothy D. ;
Moller, Henrik ;
Fearn, Paul ;
Eastham, James ;
Scardino, Peter ;
Cuzick, Jack ;
Reuter, Victor E. ;
Foster, Christopher S. .
BJU INTERNATIONAL, 2007, 100 (06) :1240-1244
[5]   GLEASON GRADING OF PROSTATIC NEEDLE BIOPSIES - CORRELATION WITH GRADE IN 316 MATCHED PROSTATECTOMIES [J].
BOSTWICK, DG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (08) :796-803
[6]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[7]  
Deshmukh N, 1998, PATHOLOGY PROSTATE
[8]   Gleason score, age and screening:: Modeling dedifferentiation in prostate cancer [J].
Draisma, Gerrit ;
Postma, Renske ;
Schroder, Fritz H. ;
van der Kwast, Theo H. ;
de Koning, Harry J. .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) :2366-2371
[9]  
EDWARDS S, 2005, AACR M ABSTR, V747
[10]   Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene [J].
Edwards, SM ;
Kote-Jarai, Z ;
Meitz, J ;
Hamoudi, R ;
Hope, Q ;
Osin, P ;
Jackson, R ;
Southgate, C ;
Singh, R ;
Falconer, A ;
Dearnaley, DP ;
Ardern-Jones, A ;
Murkin, A ;
Dowe, A ;
Kelly, J ;
Williams, S ;
Oram, R ;
Stevens, M ;
Teare, DM ;
Ponder, BAJ ;
Gayther, SA ;
Easton, DF ;
Eeles, RA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (01) :1-12